Executive Summary
CMS opened the door wider for TAVR eligibility with a proposed National Coverage Determination (CAG-00430R), arriving the same week European Heart Journal published an editorial from Filippo Crea conceding the TAVR-vs-SAVR "saga continues" and a new low-risk network meta-analysis in the Indian Journal of Thoracic and Cardiovascular Surgery reported significantly higher long-term mortality for mixed-platform TAVR versus SAVR beyond 3 years (OR 1.96, 95% CI 1.62–2.38). Meanwhile Circulation: Cardiovascular Interventions reported that adding Medicare Advantage claims to the TVT Registry lifts linkage from 57% to 87%, finally making real-world TAVR surveillance representative — right as the coverage envelope expands. These findings tighten the case for platform-specific, age-anchored decisions and complicate any blanket "TAVR for everyone" narrative.
- Low-risk network meta-analysis of 37,741 patients: TAVR-BE reduced 30-day stroke (OR 0.53), AF, AKI, and bleeding vs SAVR, but SAVR retained lower PVL and pacemaker rates at every horizon — IJTCVS.
- An AI-ECG model trained on preoperative tracings predicted 3-year post-TAVR mortality with AUC 0.71–0.77; high-risk patients died at 61.5% vs 16.5% (adjusted HR 3.49) — JACC: Asia.
- TVT Registry linkage to combined Medicare FFS + MA claims raised Hispanic linkage 2.26-fold and Black linkage 1.91-fold, fixing a growing surveillance gap — Circulation: CVI.
- Aortic angulation >55.5° cut SE-TAVR technical success from 84.3% to 75.1%, driven by second-valve implantation (19.6% vs 8.8%) in tricuspid anatomy — Heart, Lung & Circulation.
- Edwards Lifesciences upgraded its 2026 structural heart sales outlook as EW shares hit +16.3% over 6 months — Simply Wall St.
What to watch: The CMS NCA-00430R proposed decision memo public comment window and its final rule — which will determine whether volume expansion follows the ESC 2025 age-70 threshold or the more conservative ACC/AHA 2020 age-65 floor.
Aortic Valve (TAVR/TAVI)
The low-risk TAVR-vs-SAVR debate has not closed — it has fragmented by platform. A network meta-analysis of 31 studies and 37,741 low-risk patients in the Indian Journal of Thoracic and Cardiovascular Surgery found comparable short- and intermediate-term mortality across TAVR-BE, TAVR-SE, and SAVR, but at ≥3 years the heterogeneous TAVR-Mixed cohort showed OR 1.96 (95% CI 1.62–2.38, p<0.001) higher mortality versus SAVR. TAVR-BE cut 30-day stroke (OR 0.53), rehospitalization (OR 0.63), AF, AKI, and bleeding — but SAVR maintained lower paravalvular regurgitation and pacemaker rates at every time horizon. ACC/AHA 2020 preserves SAVR as the anchor recommendation for patients under 65 on exactly these durability grounds; this analysis supplies empirical support for that position. The exploratory ≥3-year signal is limited to 10 studies with mixed valve populations and demands cautious interpretation — but it sits uneasily with ESC 2025's move to age 70 as the TAVI-preferred threshold. The accompanying EHJ editorial by Filippo Crea acknowledging "the saga continues" signals that European guideline writers are watching durability signals closely and have not declared the question settled. Separately, a Chinese SE-TAVR cohort of 519 patients found aortic angulation >55.5° dropped technical success to 75.1% from 84.3%, driven by second-valve implantation (19.6% vs 8.8%) — anatomy still trumps technology.
Two papers refine post-TAVR risk stratification. The AI-ECG mortality model (711 patients, 2 centers) stratified 3-year all-cause death with adjusted HR 3.49 for high-risk classification — a noninvasive tool that outperforms clinical scores at capturing subclinical electrophysiologic risk, though the two-center retrospective design limits generalizability. A Japanese nationwide EMR analysis of 781 patients showed frailty did not independently predict AKI (OR 1.42, 95% CI 0.83–2.45) but added 3.45 days to hospitalization — frailty screening is a resource-planning tool, not a risk-exclusion filter. The CRT 2026 "Beyond the Guidelines" summary maps the residual equipoise: asymptomatic AS, bicuspid anatomy, and TAV-in-TAV failure remain the three gaps neither ACC/AHA 2020 nor ESC 2025 resolved.
Mitral Valve (MitraClip, PASCAL, TMVR)
Real-world M-TEER surveillance is now substantially more representative. The TVT Registry–Medicare linkage study in Circulation: Cardiovascular Interventions showed that adding Medicare Advantage claims to fee-for-service raised M-TEER linkage rates sharply, with the same 1.91-fold Black and 2.26-fold Hispanic representation gains seen in TAVR. This matters: MA now covers a rising share of the eligible M-TEER population, and FFS-only surveillance has been systematically underweighting minority outcomes precisely as ESC 2025's upgrade of TEER for ventricular SMR to Class I — versus ACC/AHA 2020's Class IIa — drives the technology into broader use. A separate endoscopic mitral valve replacement case in severe MAC demonstrates the posterior pericardial patch technique with automated suture fastener achieving trivial paravalvular leak — a reminder that severe MAC remains a surgical problem in patients unsuitable for TMVR, and that ACC/AHA 2020 Class I repair-first guidance for primary MR has a durable technical basis. ESC 2025's Class I upgrade for asymptomatic primary MR with adverse features (AF, SPAP, LA dilation, concomitant TR) is where the referral shift will show up first in registry data now that surveillance is population-representative.
Tricuspid Valve (TriClip, TTVR)
No dedicated TR randomized data today, but the CMS NCA and TVT linkage story matter indirectly for tricuspid: as ESC 2025 elevates transcatheter TV therapy to Class IIa and TRISCEND II real-world outcomes populate the registry, the surveillance infrastructure must keep pace. A Polish expert consensus on infective endocarditis after transcatheter valve interventions quantified TAVR-related IE at 0.3–2.0 per 100 person-years with high mortality; TEER-related IE is rarer but similarly lethal. As tricuspid transcatheter therapy expands into a frailer, device-loaded population, IE surveillance and multimodality imaging — gated cardiac CT, PET — will need to scale with volume. ESC 2025 Class I for concomitant TV surgery during left-sided operations in severe TR remains the surgical anchor; no transcatheter option has approached that threshold or the evidence base behind it.
Surgical vs. Transcatheter Comparisons
The low-risk network meta-analysis is the headline head-to-head. The finding is not that TAVR is worse overall — it is that platform matters and follow-up matters. TAVR-BE achieved comparable mortality with better periprocedural safety at all horizons; SAVR retained lower PVL and pacemaker rates; the heterogeneous TAVR-Mixed pooled cohort showed a mortality penalty beyond 3 years (OR 1.96, 95% CI 1.62–2.38). That is the empirical basis for ACC/AHA 2020's continued SAVR-first stance in low-risk patients under 65. It sits uneasily with ESC 2025's shift to age 70 as the TAVI-preferred threshold — a threshold set on the basis of DEDICATE, PARTNER 3, and Evolut Low Risk data that the EHJ editorial itself acknowledges remains incomplete beyond 5–10 years.
Device & Technology
Two device-related items. A salvage self-expanding Venus-P deployment after Cheatham Platinum prestent embolization during transcatheter pulmonary valve implantation — trapping the embolized stent against the MPA wall to avoid emergency surgery — demonstrates the value of platform versatility in complication management. A European Heart Journal Imaging methods and practice review of cardiac CT–derived ECV (ECVCT) argues for integrating myocardial tissue characterization into pre-TAVR planning workflows; opportunistic amyloid screening during procedural CT is the most immediately actionable use case. Photon-counting CT may eventually eliminate the delayed acquisition step, but standardization and reference ranges remain unresolved.
Regulatory & Policy
CMS released its proposed National Coverage Determination memo (CAG-00430R) on TAVR, and a ClickOnDetroit report frames the practical effect: less-invasive valve replacement now available to lower-surgical-risk patients under Medicare. This ratifies what commercial low-risk approvals already enabled but formalizes the reimbursement architecture. The critical question — buried in the memo — is which volume and institutional-experience requirements survive. The 2019 NCD's dual-operator and volume thresholds have been targets of criticism; loosening them expands access but risks quality dilution at low-volume centers. Combined with the TVT Registry MA linkage upgrade, US structural heart surveillance is entering a more capable era just as the coverage envelope expands.
Clinical Trial Updates
The CRT 2026 "Beyond the Guidelines" summary flags the three trials the field is watching: expanded asymptomatic AS RCTs beyond EARLY TAVR; dedicated BAV TAVR trials (NOTION-2 remains under-powered at 100 BAV patients); and TAV-in-TAV registries as first-generation TAVR valves reach end-of-durability. Combined with the low-risk network meta-analysis and the AI-ECG risk model, the trial infrastructure is now aimed at durability and phenotype-specific outcomes, not registration endpoints.
Financial Analysis
Edwards Lifesciences' upgraded 2026 structural heart sales outlook lands the same week as the CMS NCA and the TAVR-BE-friendly low-risk network meta-analysis — three tailwinds converging. EW at +16.3% over six months reflects the market pricing in the ESC 2025 Class I ventricular SMR upgrade for M-TEER plus expanded TAVR eligibility. Institutional flow confirmed by Assenagon's 547K share acquisition and ABN AMRO's 525K share addition. Boston Scientific's -33.5% six-month drawdown continues to weigh on the peer group despite a buy consensus at $62.69 — the divergence between EW and BSX reflects platform mix: BE-heavy structural heart franchise versus a more diversified electrophysiology and complex PCI story.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $89.32, +0.39% daily, +16.30% over 6 months
- Market cap: $51.4B | Trailing P/E: 52.85 | Forward P/E: 26.46 | Beta: 0.85 | 52-week range: $72.30–$96.29
- Analyst consensus: buy, target $100.96 (26 analysts, range $84–$110)
- Next earnings: Oct 29, 2026 (EPS est $0.74, Rev est $1.68B)
Upgraded 2026 structural heart sales outlook plus CMS coverage expansion sets the near-term thesis. The trailing P/E of 52.85 remains elevated; forward P/E of 26.46 reflects consensus that TAVR + M-TEER volume growth compresses the multiple. Fund accumulation (Assenagon, ABN AMRO) signals institutional confidence in the ESC 2025 tailwind.
Medtronic (MDT)
- Close: $85.92, -0.08% daily, -14.02% over 6 months
- Market cap: $110.0B | Trailing P/E: 23.03 | Forward P/E: 13.40 | Beta: 0.57 | 52-week range: $73.31–$106.33
- Analyst consensus: buy, target $98.44 (25 analysts, range $78–$121)
- Next earnings: Sep 1, 2026 (EPS est $1.39, Rev est $9.55B)
Evolut franchise remains the structural heart anchor but MDT's diversified portfolio dilutes the TAVR narrative. The 6-month drawdown reflects broader concerns beyond valve.
Abbott (ABT)
- Close: $107.96, +2.13% daily, -1.49% over 6 months
- Market cap: $188.0B | Trailing P/E: 34.27 | Forward P/E: 17.81 | Beta: 0.58 | 52-week range: $81.97–$137.49
- Analyst consensus: buy, target $118.42 (24 analysts, range $103–$135)
- Next earnings: Oct 14, 2026 (EPS est $1.42, Rev est $12.99B)
TriClip's ESC 2025 Class IIa tailwind supports the structural heart franchise; the 2.13% daily move reflects renewed enthusiasm around the tricuspid story after TRILUMINATE and TRISCEND real-world data.
Boston Scientific (BSX)
- Close: $49.30, +3.27% daily, -33.49% over 6 months
- Market cap: $71.4B | Trailing P/E: 19.33 | Forward P/E: 14.34 | Beta: 0.57 | 52-week range: $42.20–$109.50
- Analyst consensus: buy, target $62.69 (29 analysts, range $44–$94)
- Next earnings: Oct 21, 2026 (EPS est $0.81, Rev est $5.26B)
The -33.5% six-month move reflects a broader reset. Analyst target range ($44–$94) captures unusually wide uncertainty about the structural heart contribution.
Anteris Technologies (AVR.AX)
- Close: A$11.55, +5.19% daily, +44.56% over 6 months
- Market cap: A$1.1B | Forward P/E: -5.30 | Beta: 0.73 | 52-week range: A$5.20–$15.47
- Analyst target: A$13.00 (1 analyst)
DurAVR THV development story continues to command a durability premium — single-analyst coverage is a reminder this remains a specialist trade.
Private companies: JenaValve Technology, J-Valve Technology, and Meril Life Sciences are private (no public equity data).
Market outlook: EW and ABT diverge from MDT and BSX because the guideline tailwinds (ESC 2025 TEER Class I, transcatheter TV Class IIa) map cleanly to their franchise concentrations. The CMS NCA proposed memo adds a domestic volume tailwind on top of the international guideline shift. The low-risk network meta-analysis complicates the durability story for very-long-follow-up cohorts, but that concern hits the mixed-platform pooled data more than any single manufacturer.
Next week the CMS NCA public comment window opens in earnest, and the field will be watching whether the final decision preserves the volume and experience thresholds that anchored the 2019 NCD — or whether reimbursement architecture finally catches up to the ESC 2025 age-70 threshold. That decision, more than any RCT, will shape 2027 US structural heart economics.